Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Axa S.A.

Axa S.A. reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 44.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 186,813 shares of the medical equipment provider’s stock after selling 149,206 shares during the period. Axa S.A. owned approximately 0.08% of Hologic worth $13,467,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Venturi Wealth Management LLC grew its position in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 261 shares during the period. EverSource Wealth Advisors LLC boosted its position in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 260 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 159 shares during the last quarter. Smithfield Trust Co increased its holdings in Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 400 shares in the last quarter. Finally, Sound Income Strategies LLC acquired a new position in Hologic during the fourth quarter worth about $60,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Down 2.6 %

Shares of NASDAQ HOLX opened at $52.73 on Tuesday. The stock has a market capitalization of $11.83 billion, a PE ratio of 16.63, a P/E/G ratio of 2.14 and a beta of 0.54. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The firm has a fifty day moving average of $60.05 and a 200-day moving average of $68.89. Hologic, Inc. has a 52-week low of $52.12 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.03 earnings per share. On average, analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

HOLX has been the subject of a number of recent research reports. Evercore ISI dropped their price objective on shares of Hologic from $65.00 to $62.00 and set an “in-line” rating for the company in a research note on Friday. Argus cut Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Leerink Partnrs lowered Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Leerink Partners cut Hologic from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of Hologic in a report on Friday. Twelve analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Hologic currently has a consensus rating of “Hold” and a consensus price target of $79.85.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.